Amid layoffs and a hit to earnings, Bristol’s new CEO shares his vision for the future; Colombia issues a compulsory license for an HIV medicine

Taking stock of the drug industry, from the lab to the medicine chest

April 25, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Courtesy Bristol Myers Squibb STAT+ | Amid layoffs and a hit to earnings, Bristol's new CEO shares his vision for the future Despite layoffs and a hit to earnings, CEO Christopher Boerner was optimistic about the company's prospects in an interview with STAT. By Matthew Herper STAT+ | Colombia issues a compulsory license for an HIV medicine and 'plants a flag for global health equity' "Colombia is planting a flag for global health equity," said Peter Maybarduk, who heads the access to medicines campaign at Public Citizen. By Ed Silverman Opinion: Shortages of generic drugs can't be blamed solely on group purchasing organizations Shortages of generic drugs are often a "common-agency problem." Breaking up group purchasing organizations might worsen the problem. By James B. Rebitzer and Robert S. Rebitzer Adobe STAT+ | Why a British hospital, and not a drugmaker, is trying to get a rare disease therapy approved Great Ormond Street Hospital for Children is trying to overcome the fact that many biopharma companies have abandoned therapies for ultra-rare diseases. By Andrew Joseph STAT+ | Vertex offers limited access to a cystic fibrosis drug in South Africa — and may undercut a court case "This is not a solution for all South African patients" and is "likely to widen the disparity between rich and poor," advocates complained. By Ed Silverman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser